Long-Term Results of MFM® Bare Stents for the Treatment of Aortic Dissection and Aortic Aneurysms - The 66th Annual Conference of the Israel Heart Society & The Israel Society of Cardiothoracic Surgery

Claude Vaislic ¹ Ralf kolvenbach ² Victor Costache ³ Andreas Greenery michel Jacobs Ivo Petrov ⁴ Reda Barchicha ⁵ Victor Costache

¹Cardio Vascular Surgery, CHP PARLY 2
²Vascular Surgery, Catholic Hospital Group
³Cardio Vascular Surgery, CLINICA POLISANO
⁴Cardiology and Angiology, Sofia University
⁵Vascular and Endovascular Surgery, HOPITAL IRIS SUD

Dragon Study Europe is an international, multicenter, prospective, non-randomized study. It is designed to evaluate safety and performance of the MFM® for the treatment of chronic type B aortic dissection.

•22 patients withChronicAorticDissection Meanage: 56,7 years[27-86]LongestFU: 5YTreatedwitha meannumberof 2,7 MFM®.

26,1% of patients withCPMS extensions. We observed

No Dissection-Related Death (no post-operatory deaths in the first 30 days) No Paraplegia Nor Stroke No Renal Impairment

No Loss of Branch Patency No Rupture No Device Failure

With a Positive aorticremodelingoccuringover time (% change comparedto baseline)

In regards withbranches occludedfromdepart, 100% branches patencyismaintainedat 12, 24, 36 48 and 60 months.

Results need to be confirmed in a larger series and at longer follow-up,

YET the MFM® appears as a safe and performant solution for AD:

-The MFM® inducespositive aorticremodeling(FL volume decreaseand TL volume increase)

-The MFM® is able to keep all branches patent during follow-up

-Has been usedsafelyin Chronic, Acute and SubacuteTBAD and Type A AD as well

Based on those data

We suggest that MFM repair should be considered for patients with aortic dissections